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Abstract The widely used histamine receptor antagonists 
terfenadine and astemizole were shown to prolong the QT 
interval in electrocardiographic recordings in cases of overdose 
or inappropriate co-medications, indicating a possible interaction 
with cardiac K+ channels. Here, terfenadine and astemizole both 
inhibited the human ether-a-go-go related gene (HERG) encoded 
channels expressed in Xenopus oocytes at nanomolar concentra- 
tions in a use- and voltage-dependent fashion. In contrast, 
inhibition of other delayed rectifier (Kvl.1 and I& or inward 
rectifier K+ channels (IRKl) was much weaker and occurred 
only at high micromolar concentrations. These results suggest 
that blockade of HERG channels by terfenadine and astemizole 
might contribute to the cardiac side effects of these compounds. 
Key words: Histamine receptor antagonist; HERG; K+ 
channel; Torsades de pointes 
1. Introduction 
Terfenadine and astemizole are widely used non-sedating 
histamine receptor antagonists. They were shown to produce 
in some patients prolongation of the QT interval in electro- 
cardiographic recordings (ECG) resulting in torsades de 
pointes, a life-threatening form of polymorphic ventricular 
tachycardia [l-3]. These observations pointed to effects of ter- 
fenadine and astemizole on repolarizing conductances in ven- 
tricular myocytes. Recently, several groups demonstrated ter- 
fenadine blockage of distinct cardiac K+ conductances [4,5], 
but the molecular identity of the blocked K+ channels re- 
mains unclear. On their molecular basis, three general classes 
of K+ channels can be distinguished [6]: slowly activating I& 
channels [7], inwardly rectifying K+ channel (for example 
IRK1 channels first described by Kubo et al. [S]) and delayed 
rectifying K+ channels (see Ruppersberg et al. [9]). The aim of 
this study was to test representatives of distinct classes of K+ 
channels expressed in Xenopus oocytes for their sensitivity to 
terfenadine, astemizole and other histamine receptor antago- 
nists in order to identify the molecular basis for their action. 
Special attention was paid to HERG channels, which are 
likely to represent in cardiac myocytes the K+ conductance 
IKr [lo]. I& contributes significantly to the action potential 
repolarizing currents, and inhibition of IKr prolongs action 
potential duration [l I]. HERG channels expressed in Xenopus 
oocytes show identical biophysical properties as the cardiac 
K+ conductance IKr [11,12]. Recently, Salata et al. [5] demon- 
strated terfenadine- and astemizole-mediated IKr inhibition in 
guinea pig cardiac myocytes. In this study we therefore tested 
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the effects of terfenadine and astemizole on HERG expressed 
in Xenopus oocytes and compared them with their effects on 
other K+ conductances. 
2. Materials and methods 
Handling and injection of Xenopus oocytes and synthesis of cRNA 
have been described previously in detail [13,14]. The two-microelec- 
trode voltage or current clamp configuration was used to record cur- 
rents or cell membrane potential changes from Xenopus laevis oocytes. 
In several sets of experiments oocytes were individually injected with 
cRNA encoding for the Kt channels HERG [lo], rat and human Is~ 
[7,15], rat Kvl.1 [13] or rat IRK1 [16]. Recordings were performed at 
22°C using a Geneclamp amplifier (Axon Instruments, Foster City, 
USA) and MacLab D/A converter and software for data acquisition 
and analysis (ADInstruments, Castle Hill, Australia). Outward cur- 
rents through HERG channels were in general evoked with 0.5 s 
depolarizing pulses from a holding potential of -80 mV to 40 mV 
at variable intervals as described later (filtered at 0.5 kHz). Tail cur- 
rents were analyzed at -85 mV. For some experiments longer depol- 
arizing pulses to distinct voltages were performed as described later. 
Outward currents through 1,~ or Kvl.1 channels were evoked with 
15 s or 0.5 s depolarizing pulses to -10 mV from a holding potential 
of -80 mV, and filtered at 10 Hz and 1 kHz, respectively. K+ inward 
currents through inwardly rectifying IRK1 channels were evoked by 
polarizing the cells for 0.5 s to -120 mV from a holding potential of 
-40 mV (filtered at 1 kHz). The amplitudes of the recorded currents 
were measured at the end of the test voltage steps; HERG currents 
were measured as the amplitude of the tail currents. The control 
solution contained (mM): NaCl 96, KC1 2, CaClz 1.8, MgCll 1, 
HEPES 5 (titrated with NaOH to pH 7.4). The microelectrodes 
were filled with 3 M KC1 solution and had resistances between 0.5 
and 0.9 MS1. Astemizole was a generous gift from Janssen Pharma- 
ceuticals (Beerse, Belgium). Terfenadine, diphenhydramine and chlor- 
pheniramine were purchased from Sigma. All histamine receptor an- 
tagonists were solubilized in DMSO as stock solutions. Data are 
presented as means with standard errors (S.E.M.), where n represents 
the number of experiments performed. Concentration-blockage rela- 
tionships were calculated with the Hill equation. A Student’s t-test 
was used to test for statistical significance, which was obtained for 
P < 0.05. 
3. Results 
Expression of I&, IRK1 and Kvl.1 channels in Xenopus 
oocytes resulted in the induction of K+ conductances with 
described activation and rectification properties [ 13,14,16]. 
Is~ and Kvl.1 induced slow and fast activating voltage-gated 
K+ conductances, respectively, while IRK1 induced an inward 
rectifier K+ conductance in Xenopus oocytes. Terfenadine at 3 
pM produced only weak effects on the above channels (Fig. 
1A). The blockade was 4.2+0.5% (n=7), 1.8f0.7% (n=7) 
and 5.5 f 0.6% (n = 7), for IsK, IRK1 and Kvl 1 channels, 
respectively. In full concentration-response experiments, terfe- 
nadine produced half-maximal block of IsK, IRK1 and Kvl.1 
channels at 29.1 f 0.8 pM (n = 7), 23.6 f 2.2 PM (n = 7) and 
34.1+ 2.9 pM (n = 7), respectively. At concentrations of 3-10 
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uM astemizole had no significant effects on these channels 
(data not shown). At the maximal soluble concentration of 
60 uM astemizole inhibited Isk, IRK1 and Kvl.1 by 
26.02 1.4% (n=5), 12.2f 1.3% (n=5) and 14.3+ 1.9% 
(n = 5), respectively. 
Expression of HERG channels resulted in a K+ conduc- 
tance with similar properties as previously described by San- 
guinetti et al. [12]. Depolarizations to potentials more positive 
than 0 mV caused a negative rectification because of a fast C- 
type inactivation [12]. Because of its negative rectification out- 
ward currents at 40 mV are small, but the tail currents at 
repolarizing steps to -85 mV are maximal after such depolar- 
izing pulses (Fig. 1B). In contrast to the K+ conductances 
described above, terfenadine (3 uM) and astemizole (1 PM) 
almost completely abolished HERG channel tail currents 
(Fig. 1B). Terfenadine and astemizole blocked both small out- 
ward currents at 40 mV and the large outward tail currents at 
-85 mV; only the blockade of tail currents was subsequently 
analyzed. The inhibition of HERG channels by terfenadine (3 
PM) and astemizole (1 PM) was 96.6? 0.7% (n = 6) and 
92.5 + 1.5% (n = 4). Subsequently complete concentration- 
blockade relationships were analyzed for HERG channels 
by terfenadine and astemizole. Fig. 2A shows an original 
trace: both terfenadine and astemizole blocked HERG chan- 
nels at submicromolar concentrations. Analysis of the data 
with the Hill equation gave ICse values of 246.1 & 28.9 nM 
(n= 6) and 48.4f 3.8 nM (n = 6) and Hill coefficients of 
1.09 + 0.07 and 1.38 f 0.08 for terfenadine and astemizole, re- 
spectively (Fig. 2B). The effects of the tested histamine recep- 
tor antagonists on HERG channels were very slowly but com- 
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pletely reversible upon washout (washout period > 30 min). 
The reasons for the slow recovery of HERG channels from 
astemizole and terfenadine block are unclear, but both block- 
ers are hydrophobic compounds which may accumulate with- 
in the membrane. 
The non-cardiotoxic histamine receptor antagonists chlor- 
pheniramine and diphenhydramine blocked HERG channels 
with a much weaker potency with ICsc values of 20.9 +_ 2.1 
uM (n=5) and 27.1 f 1.5 pM (n=5; Fig. 2B). 
Blockade of HERG channels by terfenadine and astemizole 
was strongly use-dependent. To analyze this use dependence 
in detail, HERG channels were activated with 0.5 s depolar- 
izing steps to 40 mV at intervals of 3 s, 12 s or 36 s in the 
presence of 0.3 uM terfenadine and 0.1 PM astemizole. It is 
obvious from Fig. 3 that the time course in which HERG 
channel blockade occurs is dramatically dependent on the 
activation frequency, but not on the time of drug superfusion. 
HERG blockade by terfenadine and astemizole occurred 
much faster at higher activation frequencies. Because the ef- 
fects of terfenadine and astemizole were only very slowly re- 
versible, the use dependence of washout could not be studied. 
HERG blockade by terfenadine and astemizole was also 
analyzed for its voltage dependence. We tested the steady- 
state effects of terfenadine (0.3 PM) and astemizole (0.1 
FM) on HERG channel tail currents after 3 s depolarizing 
prepulses to -20 mV and 20 mV. Terfenadine blocked 
HERG channel tail currents by 47.0 + 9.5% (n = 6) after depo- 
larizing steps to -20 mV and by 66.2 f 7.6% (n = 6) at 20 mV 
(Fig. 4A,B). 50 nM astemizole blocked HERG tail currents by 
54.5 + 2.9% (n = 6) and 84.5 f 1.5% (n = 6), after prior depolar- 
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Fig. 1. (A) Effects of 3 pM terfenadine on Isk. IRK1 and Kvl.1 channels expressed in Xenopus oocytes. I& or Kvl.1 were evoked with 15 s or 
0.5 s voltage steps to -10 mV from a holding potential of -80 mV every 45 s or 3 s, respectively. IRK1 channels were evoked with 0.5 s po- 
larizing pulses to -120 mV from a holding potential of -40 mV. (B) Effects of 3 pM terfenadine or 1 uM astemizole on HERG channels. 
Current was evoked with 0.5 s depolarizing pulses to 40 mV from a holding potential of -80 mV every 3 s. Tail currents were recorded at 
-85 mV. 
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Fig. 2. (A) Original traces show the dose-dependent blockade of 
HERG channels by terfenadine and astemizole. (B) Concentration 
blockade correlation of astemizole, terfenadine, diphenhydramine 
and chlorpheniramine on HERG channel tail currents. Data are giv- 
en as arithmetic means (+ S.E.M.) 
izations to -20 mV and 20 mV, respectively. Both terfenadine 
and astemizole mediated HERG blockade depended signifi- 
cantly on the voltage. 
Finally, terfenadine and astemizole were also tested for 
their effects on HERG channel activation (at -20 mV) and 
deactivation kinetics (at -85 mV). Neither compound affected 
HERG channel rate of activation and deactivation at the 
described voltages (data not shown). 
4. Discussion 
Under certain conditions (overdose, liver disease or using 
simultaneously other drugs known to inhibit hepatic metabo- 
lism) terfenadine can produce QT interval prolongation in the 
ECG and syncope or cardiac arrest [17]. Similarly, astemizole 
has also been shown to produce manifest cardiac abnormal- 
ities in some rare, exceptional clinical cases associated with 
extreme astemizole overdose or inappropriate co-medications 
[2,3]. No reports exist about any adverse cardiovascular effects 
for chlorpheniramine and diphenhydramine.In this study we 
expressed representatives of distinct K+ channel families in 
Xenopus oocytes and tested them for their sensitivity to terfe- 
nadine and astemizole. Both compounds blocked K+ currents 
through HERG channels during depolarizations as well as 
repolarizations. This result supports the notion that blockade 
of HERG channels is the major reason for QT interval pro- 
longation caused by terfenadine and astemizole. Most impor- 
tantly, in this study both compounds blocked HERG channels 
expressed in Xenopus oocytes at concentrations similar to the 
plasma concentrations in patients with terfenadine or astemi- 
zole induced QT prolongation. Moreover, blockade of Ikr (the 
conductance induced by HERG channels in human cardiac 
myocytes) by o-sotalol or its derivatives is also known to 
cause QT prolongation [12]. Finally, the genetic defect of 
HERG causes a QT syndrome [18]. These reports support 
that both HERG inhibition and dysfunction can indeed in- 
duce QT prolongation. 
Several other studies have observed inhibitory effects of 
terfenadine also on other K+ channels: the delayed rectifier 
fHK (Kv1.5), which was cloned from human heart and stably 
expressed in HEK-293 cells, was blocked with an I&O of 0.4 
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Fig. 3. Use-dependent HERG channel blockade by 0.3 PM terfena- 
dine (A) or 0.1 pM astemizole (B). Tail currents were recorded at 
-85 mV after a 0.5 s depolarizing prepulse to 40 mV from a hold- 
ing potential of -80 mV every 3 s, 12 s or 36 s. The solution flow 
rate was 20 ml/min, ensuring a complete exchange of the bath solu- 
tion within lCL15 s. Before starting with the first depolarizing pulse 
(time= 0) the oocytes were superfused for 30 s with the drug con- 
taining solution to ensure complete and safe exchange of the bath. 
The drug effects were recorded in distinct sets of experiments with 
different intervals (3 s, 12 s and 36 s) between the depolarizing 
steps. For clarity not all data points for 3 s and 12 s intervals are 
given in the graph. For the set of experiments with 36 s intervals 
between the depolarizing steps all data are given. Data are given as 
arithmetic means (? S.E.M.). 
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(A) result supports a preferred binding of terfenadine and astemi- 
zole to inactivated HERG channels. 
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Fig. 4. (A) Original trace showing the voltage dependence of terfe- 
nadine on HERG. Currents were evoked with 3 s depolarizing 
pulses to -20 mV and 20 mV, respectively, from a holding poten- 
tial of -80 mV every 5 s. Only the effects on the tail currents were 
calculated. (B) Voltage-dependent block of 0.3 uM terfenadine and 
50 nM astemizole on HERG tail currents (n = 6; P < 0.05). 
/LM [19], an I& similar to the value for HERG channels in 
the present study. However, in contrast to the clearly defined 
role of HERG channels in human heart, the effects of Kv1.5 
inhibition on the ECG are not clear yet. In any case, these 
studies suggest that terfenadine may interfere with more than 
one type of K+ channel. However, terfenadine blocks HERG 
with relatively high potency. In the present study the terfena- 
dine sensitivity of HERG channels exceeded that of other K+ 
channels by two orders of magnitude. Astemizole was clearly 
more specific for HERG channels with a more than lOOO-fold 
higher potency compared to I&, Kvl.1 and IRKl. 
The extreme use dependence of terfenadine and astemizole 
suggests that drug binding can only occur to the open or 
inactivated state of HERG channels. Two observations favor 
binding to the inactivated state of HERG channels. (1) If 
terfenadine and astemizole bound and unbound only to and 
from open channels one would predict a smaller z,:~ and a 
greater qjea,--. However, both terfenadine and astemizole had 
no effects on the rate of HERG channel activation and deac- 
tivation. (2) Steady-state blockade of HERG by terfenadine 
and astemizole was voltage-dependent and greater at more 
positive potentials. Because at more positive potentials more 
HERG channels transfer to the inactivated state [12], this 
In summary, the present study demonstrates potent block- 
ade of HERG channels by the histamine receptor antagonists 
terfenadine and astemizole. This channel blockade is likely to 
be involved in the prolonged QT intervals observed in certain 
patients. 
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